Core Insights - Kingsray Biotech (1548.HK) held its first Investor Open Day on November 12, revealing its strategic blueprint for 2035, transitioning from a "R&D service provider" to a "biotechnology ecosystem platform" [1][2] - Following the event, the company's stock price rose by 8% over three days, indicating strong market confidence [1] - The strategic upgrade aims to reshape the company's investment value amid a critical period of restructuring in the global biopharmaceutical industry [1] Strategic Framework - CEO Shao Weihui outlined a five-phase development strategy from 2002 to 2035, with specific goals including $3 billion in regular business revenue and an operating profit margin exceeding 20% by 2035 [2][3] - The company aims for cumulative licensing revenue of $3 billion, with product revenue accounting for over 50% and high-margin area revenue exceeding 80% [2][3] Business Strategy - The business strategy is structured into a "H1+H2+H3+synergy" matrix: - H1 focuses on core businesses like gene and plasmid production, providing stable revenue and cash flow [4] - H2 targets high-growth potential markets such as LVV/LNP/gene editing and life science instruments [4] - H3 seeks explosive growth through innovative services and products [4] Life Sciences Division - The Life Sciences division is transitioning from a "gene synthesis leader" to a "technology platform-driven ecosystem," with significant advancements in platforms like FlashGene™ and TurboCHO™ [6] - TurboCHO™ platform has achieved rapid delivery of antibodies, with sales growth exceeding 50% year-on-year in the first half of 2025 [6] - The division expects a compound annual growth rate of 15%-20% in revenue from 2025 to 2028 [6] Financial Goals - The company has set ambitious financial targets, including a revenue compound growth rate of 18%-25% for its synthetic biology products and a significant increase in international revenue [15][17] - The current market valuation is seen as undervalued, with a potential upside of approximately 42% based on recent reports [19][22] Conclusion - Kingsray's Investor Open Day presented a clear strategic roadmap, emphasizing business synergy and ecosystem development [19] - The company is poised for a valuation reappraisal as it moves towards becoming a global leader in biotechnology, driven by technology and ecosystem empowerment [19]